null
A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without

A phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND

A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Investigate the use of Benralizumab compared to Mepolizumab for Patients with

A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)

A Phase 2, Open-label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension

A Randomized, Double-Blind, Placebo Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-line Platinum-Based Chemotherapy

A phase II Trial of E7080/MK-7902 (Lenvatinib) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006) and older with moderate to severe atopic dermatitis

A randomized, double-blind, multicentre study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 sub cutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa

A phase I/II study of olaparib in BRCA1 and BRCA2 mutation carriers with non-metastatic platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

A phase I/II study of the safety, tolerability and pharmacokinetics of a single dose of AD0485 in healthy volunteers

A randomized phase I trial of the immunomodulatory cytokine, IL-6R antagonist, AMG 510, administered as subcutaneous injection in patients with active rheumatoid arthritis

A phase I/II study of RLX-590 in patients with psoriatic arthritis (PsA)

A phase II, Mutational, Randomized, double-blind, placebo-controlled, Parallel-group trial examining the safety and efficacy of guselkumab + methotrexate (MTX) versus MTX alone in patients with moderate to severe plaque psoriasis

A phase I, Multicentre, Randomised, Double-blind, Placebo-controlled trial to investigate the effect of DPP-4 inhibitors on 24-hour ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus

A phase I, Multicentred, Randomised, Parallel-Group Study to Evaluate the Effectiveness and Safety of Rilonacept in Patients with Polyarticular Juvenile Idiopathic Arthritis

A phase I/II/III, Multicenter, Open-label, Parallel-group Study Evaluating the Exploratory Efficacy and Safety of Cardioprotective Dosing of BMS-986022 in Patients undergoing Percutaneous Coronary Intervention and treating Type 2 Diabetes Mellitus

A randomized phase II/III, open-label, multicentre study of the use of Ruxolitinib in polycythemia vera patients with intermediate or high-risk disease

A phase II, Multicentric, Randomized, placebo-controlled, parallel-group study evaluating the efficacy and safety of 4 weeks of tocilizumab treatment in patients with active rheumatoid arthritis

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Subjects with Primary Progressive Multiple Sclerosis

A phase II trial of Olaparib in advanced ovarian cancer patients: primary end-point of antitumor activity

A phase I/II study of olaparib in BRCA1 and BRCA2 mutation carriers with non-metastatic platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tebentafusp Tepluvec in Patients with Metastatic Melanoma and no Previous Systemic Therapy

A phase II/III trial of E20065 in the treatment of myelodysplastic syndromes (MDS)

A randomized, placebo-controlled, double-blind, dose-escalating study of the safety, tolerability and pharmacokinetics of a single dose of Nilotinib in healthy volunteers

A phase II, Open-label, Multicentre, Parallel-group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anexin in Patients with Systemic Sclerosis (SSc) and/or Scleroderma (Scl)

A phase II, Randomized, Double-blind, Placebo-controlled, parallel group study to evaluate efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) and no previous anti-TNF therapy

A phase I, Double blind, randomized, placebo controlled, parallel group study evaluating the safety and efficacy of mifepristone and misoprostol for medical abortion in women

A phase II/III, Randomized, double-blind, placebo-controlled multicenter trial to evaluate the extension of the safety and tolerability findings identified in phase I/II trials in patients with chronic lymphocytic leukemia (CLL)

A phase II, Multicenter, Parallel-group, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Patients with Metastatic Locally Advanced or Metastatic Non-small Cell Lung Cancer

A randomized phase II/III study of olaparib in advanced ovarian cancer patients with a germline BRCA1 or BRCA2 mutation

A phase III, Randomized, Double-blind, Placebo-controlled Study of E7080/MK-7902 (Lenvatinib) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006) and older with moderate to severe atopic dermatitis

A phase I, Multicentred, Randomised, Parallel-Group Study to Investigate the Effectiveness and Safety of Rilonacept in Patients with Polyarticular Juvenile Idiopathic Arthritis

A phase I trial of the use of recombinant human TGF-β1 in the treatment of psoriasis

A phase II study of ertugliflozin compared to placebo in patients with type 2 diabetes mellitus: dose-ranging phase

A randomized, double-blind, placebo-controlled, parallel-group study evaluating the safety and tolerability of 8 weeks of tocilizumab treatment in patients with active rheumatoid arthritis
<table>
<thead>
<tr>
<th>No</th>
<th>Research Ethics Committee Reference Number</th>
<th>Integrated Research Application System Number</th>
<th>Name of Trial</th>
<th>Date Site Ready to Start</th>
<th>Date Site Confirmed</th>
<th>Date Site Selected</th>
<th>Date of First Participant Recruited</th>
<th>Non Confirmation Status</th>
<th>Date of First Participant Unrecruited</th>
<th>Date Site Ready to Start</th>
<th>Date Site Confirmed</th>
<th>Date Site Selected</th>
<th>HRA Approved Date</th>
<th>Date of Initial Sponsor Review</th>
<th>Reasons for delay</th>
<th>Date of First Participant Recruited</th>
</tr>
</thead>
<tbody>
<tr>
<td>152</td>
<td></td>
<td></td>
<td>A Randomized, Double-blind, Controlled Trial to Evaluate the Efficacy and Safety of Xemomin for the Treatment of MG and Related Conditions.</td>
<td>21/01/2020</td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>31/01/2020</td>
<td>Neither</td>
<td></td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>31/01/2020</td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>Xemomin proprietary considerations</td>
<td></td>
</tr>
<tr>
<td>153</td>
<td></td>
<td></td>
<td>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Devexin for the Treatment of MG and Related Conditions.</td>
<td>22/01/2020</td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>31/01/2020</td>
<td>Neither</td>
<td></td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>31/01/2020</td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>Devexin proprietary considerations</td>
<td></td>
</tr>
</tbody>
</table>

**Performance in Initiating Clinical Research**

HRA Approval: 1 April 2019 to 31 March 2020

**Selected Date**

<table>
<thead>
<tr>
<th>Date Site Ready to Start</th>
<th>Date Site Confirmed</th>
<th>Date Site Selected</th>
<th>HRA Approved Date</th>
<th>Date of Initial Sponsor Review</th>
<th>Reasons for delay</th>
<th>Date of First Participant Recruited</th>
</tr>
</thead>
<tbody>
<tr>
<td>21/01/2020</td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>31/01/2020</td>
<td>30/01/2020</td>
<td>Xemomin proprietary considerations</td>
<td></td>
</tr>
<tr>
<td>22/01/2020</td>
<td>30/01/2020</td>
<td>30/01/2020</td>
<td>31/01/2020</td>
<td>30/01/2020</td>
<td>Devexin proprietary considerations</td>
<td></td>
</tr>
</tbody>
</table>